Star Imaging and Path Lab Q4 FY26 Results: PAT Rs 9 Cr

Star Imaging and Path Lab Q4 FY26 results were declared on May 22, 2026. The company reported PAT of Rs 9 crore for the quarter ended March 31, 2026, down 10.0% YoY compared to Rs 10 crore in Q4 FY25. Revenue stood at Rs 43 crore, for the quarter ended March 31, 2026. Results are on a Consolidated basis. Star Imaging and Path Lab is a Diagnostics company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Star Imaging and Path Lab Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	Rs 43 crore	Rs N/A crore	N/A
Net Profit	9	10	-10.0%
Basis	Consolidated

Note: Star Imaging and Path Lab Q4 FY26 results declared May 22, 2026. Data sourced from Screener.in/BSE filings. Verify from audited filings before investment decisions.

Star Imaging and Path Lab Q4 FY26 Performance Analysis

The Star Imaging and Path Lab Q4 FY26 results reflect the company’s performance in the January to March 2026 quarter. The company delivered results in line with sector trends. Star Imaging and Path Lab operates in the Diagnostics segment, benefiting from India’s GDP growth above 6.5% and domestic demand conditions in FY26.

Revenue of Rs 43 crore was for the quarter ended March 31, 2026. Steady revenue reflects consistent business conditions.

Screen the best stocks on the Univest Screener.

Key Factors Driving Star Imaging and Path Lab Q4 FY26 Results

Revenue and Business Performance

Revenue of Rs 43 crore in Star Imaging and Path Lab Q4 FY26 was for the quarter ended March 31, 2026. Stable revenue momentum reflects consistent operational delivery. The January to March 2026 quarter is the year-end quarter for Indian companies, characterised by strong order execution and fiscal year-end activity.

Profitability and Margin Trends

The Star Imaging and Path Lab Q4 FY26 PAT of Rs 9 crore down 10.0% YoY. Stable profitability reflects consistent operational delivery.

India Macro Environment Q4 FY26

India’s macro environment in Q4 FY26 was supportive, with GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption. The RBI’s accommodative stance supported credit and demand conditions. For Star Imaging and Path Lab operating in the Diagnostics sector, these macro tailwinds provided a constructive backdrop entering FY27.

FY27 Outlook

Following the firm results, management guidance on FY27 revenue trajectory, margin improvement, and capital allocation will be key investor watchpoints. The Diagnostics sector continues to benefit from India’s structural growth drivers including urbanisation, infrastructure investment, and rising middle-class consumption.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the company

Investments in securities are subject to market risk. This content is for educational purposes only. Verify from BSE/NSE filings. Consult a SEBI-registered financial advisor.